Actavis Announces Agreement with Aurobindo Pharma to Divest Commercial Operations in Seven Western European Countries
Actavis (NYSE: ACT) today announced that it intends to enter into an agreement for Aurobindo Pharma to acquire Actavis' generics commercial operations in seven markets in Western Europe. The transaction is conditional on certain antitrust approvals and completion of employee consultation processes.
Aurobindo would acquire Actavis' pharmaceutical commercial infrastructure in France, Italy, Spain, Portugal, Belgium, Germany and the Netherlands, including products, marketing authorizations and dossier license rights. The two companies would also enter into a long-term strategic supply arrangement.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.